about
The Promise of Preventive Cancer VaccinesMet receptor acts uniquely for survival and morphogenesis of EGFR-dependent normal mammary epithelial and cancer cells2H,3H-decafluoropentane-based nanodroplets: new perspectives for oxygen delivery to hypoxic cutaneous tissuesCharacterization of a genetic mouse model of lung cancer: a promise to identify Non-Small Cell Lung Cancer therapeutic targets and biomarkers.Identification of relevant conformational epitopes on the HER2 oncoprotein by using Large Fragment Phage Display (LFPD).Nonredundant roles of antibody, cytokines, and perforin in the eradication of established Her-2/neu carcinomas.microRNA-214 contributes to melanoma tumour progression through suppression of TFAP2C.HER2-based recombinant immunogen to target DCs through FcγRs for cancer immunotherapy.Critical roles of specimen type and temperature before and during fixation in the detection of phosphoproteins in breast cancer tissues.Antitumor immunization of mothers delays tumor development in cancer-prone offspring.Bovine herpesvirus 4-based vector delivering a hybrid rat/human HER-2 oncoantigen efficiently protects mice from autochthonous Her-2(+) mammary cancerChimeric DNA Vaccines against ErbB2+ Carcinomas: From Mice to Humans.Early onset and enhanced growth of autochthonous mammary carcinomas in C3-deficient Her2/neu transgenic mice.Zoledronic acid repolarizes tumour-associated macrophages and inhibits mammary carcinogenesis by targeting the mevalonate pathway.Vaccines against human HER2 prevent mammary carcinoma in mice transgenic for human HER2.DNA vaccination against oncoantigens: A promise.The rat ErbB2 tyrosine kinase receptor produced in plants is immunogenic in mice and confers protective immunity against ErbB2(+) mammary cancer.miR-214 coordinates melanoma progression by upregulating ALCAM through TFAP2 and miR-148b downmodulation.miR148b is a major coordinator of breast cancer progression in a relapse-associated microRNA signature by targeting ITGA5, ROCK1, PIK3CA, NRAS, and CSF1.Protective immunity against neu-positive carcinomas elicited by electroporation of plasmids encoding decreasing fragments of rat neu extracellular domain.The non-inflammatory role of C1q during Her2/neu-driven mammary carcinogenesis.A limited autoimmunity to p185neu elicited by DNA and allogeneic cell vaccine hampers the progression of preneoplastic lesions in HER-2/NEU transgenic mice.Protection of mice against the highly pathogenic VVIHD-J by DNA and fowlpox recombinant vaccines, administered by electroporation and intranasal routes, correlates with serum neutralizing activity.miR-135b coordinates progression of ErbB2-driven mammary carcinomas through suppression of MID1 and MTCH2.The adjuvant activity of BAT antibody enables DNA vaccination to inhibit the progression of established autochthonous Her-2/neu carcinomas in BALB/c mice.A better immune reaction to Erbb-2 tumors is elicited in mice by DNA vaccines encoding rat/human chimeric proteins.Insertion of the DNA for the 163-171 peptide of IL1beta enables a DNA vaccine encoding p185(neu) to inhibit mammary carcinogenesis in Her-2/neu transgenic BALB/c mice.Electroporated DNA vaccine clears away multifocal mammary carcinomas in her-2/neu transgenic mice.Strengths and Weaknesses of Pre-Clinical Models for Human Melanoma Treatment: Dawn of Dogs' Revolution for Immunotherapy.Multiple roles of perforin in hampering ERBB-2 (Her-2/neu) carcinogenesis in transgenic male mice.Immune prevention of mammary carcinogenesis in HER-2/neu transgenic mice: a microarray scenario.Inhibition of mammary carcinogenesis by systemic interleukin 12 or p185neu DNA vaccination in Her-2/neu transgenic BALB/c mice.Ability of systemic interleukin-12 to hamper progressive stages of mammary carcinogenesis in HER2/neu transgenic mice.Oncoantigens as anti-tumor vaccination targets: the chance of a lucky strike?Concordant morphologic and gene expression data show that a vaccine halts HER-2/neu preneoplastic lesionsInterleukin 12-activated lymphocytes influence tumor genetic programsChimeric DNA Vaccines: An Effective Way to Overcome Immune ToleranceCSPG4-Specific Immunity and Survival Prolongation in Dogs with Oral Malignant Melanoma Immunized with Human CSPG4 DNASecond Ascoli Piceno conference on gene vaccination in cancer (GVC), Ascoli Piceno, Italy, October 9–11, 2013DNA immunization using constant-current electroporation affords long-term protection from autochthonous mammary carcinomas in cancer-prone transgenic mice
P50
Q26783742-4435697D-8417-46B4-8B66-6B7B4DFFBBF7Q27318931-B5023A57-B385-42A8-9D02-048E7975438AQ30416282-535763C9-ACA5-4B4B-9085-46C9518BFD6DQ33851540-67515AA7-4C1E-4810-81BF-5153D567862DQ34650345-4621A966-479E-4265-87BB-4BF70D55F0BDQ34912810-8BE18191-DB51-4F94-8F4F-852126948474Q34993968-CA58D0BD-0946-4B1F-AFC9-EDD4849B19C0Q35556207-40C54009-8B68-4616-ACF8-72B490E4B60CQ35574950-E309C79D-EB51-4B11-B9FA-686A65289D68Q35799346-5D93A9BE-F4C9-4B27-AC10-AA7BF79A3821Q36821263-DF50742B-6F4A-4FB3-8133-6634E81BF7C7Q37137404-158875E6-C879-4316-8DD7-AA86A74E5394Q37289084-1B4E0D47-5BA9-4284-B8E1-360966CA7DE2Q37294327-EA993D0E-5784-4C3C-97C6-133253BB4869Q37691212-779C3021-42B0-4E78-8DD9-A818C5ECAB9DQ38022032-834DEAC9-DB61-4043-A881-75CF60C454CCQ38888368-8484FF42-A42A-4831-A2D3-AE44DC3E9AD2Q39153011-6E727D86-6068-4D0B-AAF8-474472CDC5F5Q39227433-ADC3C723-1DC1-48EE-8F43-274779C6C085Q40013967-6699A2EA-E134-4BC2-A309-9AF6340A2243Q40357845-A3EB4FE3-A5A2-4AB6-8EDE-A8B413A87669Q40423857-9FAE11C8-4F37-4370-96A3-282F251A5133Q40537456-90D4F8CE-C5ED-4AFC-B848-155F9F39969DQ42437801-A0A1ED98-18C8-46EB-9F5E-2373CD30AAE9Q42815809-FB9555F5-A80B-4B56-A236-739FEAAC4227Q42828238-24B2D089-C522-49BF-B036-E3F3781B04AEQ45876548-CB5CFD38-BFEA-4F25-BB60-4AACC92C9DD3Q47755247-73B87125-C39A-4BC2-9775-60C5C4257C44Q52657766-BE1436B0-5B63-4A8B-AE99-EC7935B1B4C5Q53238322-5DFD8E60-0AC9-4D8E-9173-AE9926DA5D36Q53361086-FFC9C5D2-8232-4B8F-B0F6-B4A6827020DAQ53399785-F8B86937-8956-431E-914D-2D2039FA8C0CQ53413754-F36CA1C9-B067-4838-A685-8E0B5495ECECQ57692977-DEE393FE-9EBD-43DA-A250-5A4770C5E015Q57693035-86529AB6-03A5-475C-BEA5-2B386F6B5E11Q57693062-5E8709E0-57C3-4695-BD44-4DE241F51035Q61822487-DACBD65B-28A7-4DEF-A098-B0721FFA4411Q61822490-879CF7A8-51CC-4DB0-8B55-5E08555210F7Q61822493-0D8F724C-BA0E-4FD2-85BD-E74522ABC173Q61822538-8DC40AFB-B51A-48EE-86A7-F15CB50936C6
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Elena Quaglino
@ast
Elena Quaglino
@en
Elena Quaglino
@es
Elena Quaglino
@nl
Elena Quaglino
@sl
type
label
Elena Quaglino
@ast
Elena Quaglino
@en
Elena Quaglino
@es
Elena Quaglino
@nl
Elena Quaglino
@sl
prefLabel
Elena Quaglino
@ast
Elena Quaglino
@en
Elena Quaglino
@es
Elena Quaglino
@nl
Elena Quaglino
@sl
P106
P1153
6603501602
P21
P31
P496
0000-0002-8151-9124